Landmark Bio Unveils New State-of-the-Art Full-Spectrum Biomanufacturing Innovation Center
New 44,000 square-foot fully integrated facility for development, manufacturing and testing of cell and gene therapies in Watertown, Massachusetts, offers end-to-end capabilities and onestop manufacturing solutions
WATERTOWN, MA, October 27, 2022 – Landmark Bio™, a collective endeavor launched byleaders from academia, the life sciences industry, and world-renowned research hospitals toaccelerate development and industrialization of next-generation genomic medicine, todayannounced the opening of its state-of-the-art full-spectrum development and biomanufacturingfacility in Watertown.
“Landmark Bio is a unique venture bringing together the best of academia, industry, andresearch hospitals to translate groundbreaking research into life-changing therapies,” said RanZheng, chief executive officer of Landmark Bio.
“By fostering a strong cross-sector collaboration, we aim to solve three critical challenges innovel therapy development – capabilities, technology, and talent. We provide expertise innovel modality product design and development, innovative manufacturing technologies, inhousequality control capabilities, and best-in-class development, regulatory and supply chainmanagement practices to enable fast to clinic with a line of sight to commercialization. We aregrateful for the generous support of our founding partners, collaborating institutions and thelife sciences community in Massachusetts as we push the frontiers of life sciences innovation toultimately benefit patients,” she added.
“This new state-of-the-art facility will bring together leading innovators from universities,research institutes, hospitals, and industries in the Greater Boston life science community,” said Alan M. Garber, M.D., Ph.D., provost, Harvard University, Mallinckrodt Professor of Health Care Policy at Harvard Medical School, professor of economics in Harvard’s Faculty of Arts and Sciences, professor of public policy in the Harvard Kennedy School of Government, andchairman of Landmark Bio’s board of directors. “Landmark Bio will be a platform that enablesgroundbreaking ideas from our laboratories to be transformed into life-changing therapies. Thework here will facilitate access to the most promising approaches to preventing and treatingillness, thanks to advances in biomanufacturing technologies.”
“This facility serves as a transformational development center for our talented researchcommunity to advance technologies that manufacture and distribute breakthrough therapies,”said MIT Provost Cynthia Barnhart, who is a member of Landmark Bio’s board of directors andthe Abraham J. Siegel Professor of Management Science and professor of operations researchat MIT.
“This opening for Landmark Bio celebrates the collaborative spirit established by the foundingmembers with the purpose of accelerating access to innovative therapies for patients,” said Emmanuel Ligner, Landmark Bio founding director and president and chief executive officer of Cytiva. “Landmark Bio is gathering the brightest minds across academia and industry, alongwith leading clinicians, to develop immediate manufacturing capabilities, and to enableinnovation and research.”
The 44,000 square-foot fully integrated development and manufacturing facility includeslaboratory space for translational research and early development, process and analyticaldevelopment and technology innovation. The biomanufacturing area is comprised of eightcleanrooms for cell therapies, genome editing, viral vector, mRNA and lipid nanoparticleproduction as well as fill and finish and in-house Quality Control (QC) testing.
In addition, Landmark Bio provides wraparound services such as drug development andregulatory consulting, program management and other support services. The facility currentlyhas about 60 staff members and will grow to more than 100 people in the coming years.
“The opening of Landmark Bio’s biomanufacturing facility is an important milestone for thecompany and Massachusetts’ world-class life sciences sector,” said Housing and EconomicDevelopment Secretary Mike Kennealy. “Landmark Bio’s continued growth is another demonstration of how our Commonwealth’s ecosystem of innovation and talent is positioningus at the leading edge of medical advancements.”
About Landmark Bio™
Landmark Bio PBLLC, a statutory public benefit limited liability company, or PBLLC, is a collective endeavor launched by leaders from academia, the life sciences industry, and worldrenowned research hospitals to accelerate the development and industrialization of noveltherapeutics. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come. Founding partners include Harvard University,Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB),, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the DanaFarber Cancer Institute. For more information, visit landmarkbio.com.
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com